150 related articles for article (PubMed ID: 2667754)
1. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
Press OW; Farr AG; Borroz KI; Anderson SK; Martin PJ
Cancer Res; 1989 Sep; 49(17):4906-12. PubMed ID: 2667754
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
3. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells.
Press OW; Howell-Clark J; Anderson S; Bernstein I
Blood; 1994 Mar; 83(5):1390-7. PubMed ID: 8118040
[TBL] [Abstract][Full Text] [Related]
4. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
5. CDw40 and BLCa-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes.
Clark EA; Yip TC; Ledbetter JA; Yukawa H; Kikutani H; Kishimoto T; Ng MH
Eur J Immunol; 1988 Mar; 18(3):451-7. PubMed ID: 2451615
[TBL] [Abstract][Full Text] [Related]
6. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells.
Geissler F; Anderson SK; Venkatesan P; Press O
Cancer Res; 1992 May; 52(10):2907-15. PubMed ID: 1581908
[TBL] [Abstract][Full Text] [Related]
7. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
8. Constitutive endocytosis and degradation of CD22 by human B cells.
Shan D; Press OW
J Immunol; 1995 May; 154(9):4466-75. PubMed ID: 7722303
[TBL] [Abstract][Full Text] [Related]
9. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
11. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
[TBL] [Abstract][Full Text] [Related]
12. Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL.
Gudowius S; Recker K; Laws HJ; Dirksen U; Tröger A; Wieczorek U; Furlan S; Göbel U; Hanenberg H
Klin Padiatr; 2006; 218(6):327-33. PubMed ID: 17080335
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40).
Ledbetter JA; Shu G; Gallagher M; Clark EA
J Immunol; 1987 Feb; 138(3):788-94. PubMed ID: 3492534
[TBL] [Abstract][Full Text] [Related]
14. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths.
Shan D; Press OW; Tsu TT; Hayden MS; Ledbetter JA
J Immunol; 1999 Jun; 162(11):6589-95. PubMed ID: 10352275
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
[TBL] [Abstract][Full Text] [Related]
17. Activation of human B cells and inhibition of their terminal differentiation by monoclonal anti-mu antibodies.
Maruyama S; Kubagawa H; Cooper MD
J Immunol; 1985 Jul; 135(1):192-9. PubMed ID: 3923101
[TBL] [Abstract][Full Text] [Related]
18. Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use.
Kvalheim G; Sørensen O; Fodstad O; Funderud S; Kiesel S; Dörken B; Nustad K; Jakobsen E; Ugelstad J; Pihl A
Bone Marrow Transplant; 1988 Jan; 3(1):31-41. PubMed ID: 3048468
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells.
Cragg MS; Zhang L; French RR; Glennie MJ
Br J Cancer; 1999 Feb; 79(5-6):850-7. PubMed ID: 10070880
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic characterisation of cord blood B-lymphocytes.
Paloczi K; Batai A; Gopcsa L; Ezsi R; Petranyi GG
Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S89-91. PubMed ID: 9916647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
